Alpha Cognition (NASDAQ:ACOG) Announces Quarterly Earnings Results

Alpha Cognition (NASDAQ:ACOG) posted its quarterly earnings data on Thursday. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.03), Zacks reports. Alpha Cognition had a negative net margin of 202.23% and a negative return on equity of 68.21%. The company had revenue of $2.60 million for the quarter, compared to analysts’ expectations of $4.41 million.

Here are the key takeaways from Alpha Cognition’s conference call:

• Strong early commercial traction — Q4 dispensed 4,941 bottles (1,859 in December), Q4 net product revenue of $2.5M and YTD product sales of $6.8M, with prescribers up 50% vs Q3 and high repeat ordering (82% of ordering homes).
• Payer progress — executed a second national PBM contract (now contracted with 2 of the top 4 PBMs); company expects downstream plan-level pull-through beginning in Q2 with broader implementation in Q3, though payer access remains a material friction point.
• Clinical and safety momentum — management reports minimal spontaneous GI adverse events, launched three real‑world studies (BEACON, CONVERGE, RESOLVE) with toplines in Q3–Q4 2026, and plans a sublingual PK study in Q2 targeting clinic entry in early 2027.
• Financial posture reflects heavier investment — FY2025 operating loss widened; 2026 operating expenses expected at $54–58M; the company holds approximately $66M in cash (post raise) providing runway into 2027 while targeting operational profitability in 2027.
• Commercial scaling initiatives — sales force expansion is largely filled, nearly 3,856 unique homes reached to date, and 48 KOLs trained for national peer‑to‑peer education intended to accelerate adoption in long‑term care.

Alpha Cognition Price Performance

NASDAQ:ACOG opened at $5.08 on Friday. The firm has a 50-day moving average of $5.57 and a two-hundred day moving average of $6.28. Alpha Cognition has a 1-year low of $3.75 and a 1-year high of $11.54. The stock has a market cap of $110.44 million, a P/E ratio of -4.38 and a beta of 2.55.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and set a $18.00 target price on shares of Alpha Cognition in a research report on Friday, December 19th. One investment analyst has rated the stock with a Buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $18.00.

Hedge Funds Weigh In On Alpha Cognition

Several hedge funds have recently made changes to their positions in the business. Geode Capital Management LLC bought a new position in Alpha Cognition in the 2nd quarter valued at about $112,000. Marshall Wace LLP bought a new stake in Alpha Cognition during the second quarter valued at $600,000. Cable Car Capital LP boosted its holdings in shares of Alpha Cognition by 68.8% during the 2nd quarter. Cable Car Capital LP now owns 869,002 shares of the company’s stock worth $8,108,000 after buying an additional 354,278 shares in the last quarter. Massar Capital Management LP bought a new stake in Alpha Cognition in the 2nd quarter valued at about $116,000. Finally, Manatuck Hill Partners LLC increased its stake in Alpha Cognition by 74.6% during the 2nd quarter. Manatuck Hill Partners LLC now owns 117,000 shares of the company’s stock valued at $1,092,000 after purchasing an additional 50,000 shares in the last quarter.

About Alpha Cognition

Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.